HEAL WELL. AGE WELL. LIVE LONGER.(800) 266-7207   ·   contact@clearhealthpass.com
Peptides / July 23, 2026

Bringing the peptide conversation to the public record.

Written submissions and public testimony are part of the Consortium’s reported FDA engagement.

FDA docket FDA-2025-N-6895: written comments, supplemental comments and public testimony, July 2026

Clear Health Pass submitted written comments to FDA Docket FDA-2025-N-6895 on July 9, 2026, supplemental comments on July 23 and public testimony in three sessions on July 23.

This is a company-reported participation history. Committee advice does not establish safety, efficacy or company program authorization.

A subsequent policy development

On October 30, 2026, the Federal Register published a notice of availability for a draft HHS enforcement-discretion policy regarding 503A compounding using certain peptide bulk drug substances. Its impact on company plans is under review.

Read the Federal Register notice ↗

Source: Federal Register 91 FR 68526, October 30, 2026.